<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004153</url>
  </required_header>
  <id_info>
    <org_study_id>9308</org_study_id>
    <secondary_id>UCCRC-9308</secondary_id>
    <secondary_id>UCCRC-CTRC-9767</secondary_id>
    <secondary_id>NCI-G99-1620</secondary_id>
    <nct_id>NCT00004153</nct_id>
  </id_info>
  <brief_title>Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma</brief_title>
  <official_title>Sensitive RT-PCR Analysis for Melanoma Markers From Lymph Nodes and Peripheral Blood in Patients With Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures may improve the ability to detect the presence or recurrence&#xD;
      of disease.&#xD;
&#xD;
      PURPOSE: Diagnostic trial to detect melanoma markers in the lymph nodes or peripheral blood&#xD;
      of patients who have melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of performing reverse transcriptase-polymerase chain reaction&#xD;
           (RT-PCR) for five different tumor antigen genes using lymph node samples or peripheral&#xD;
           blood from patients with melanoma.&#xD;
&#xD;
        -  Determine the ability of PCR-positive lymph nodes or peripheral blood to predict relapse&#xD;
           of disease in these patients.&#xD;
&#xD;
        -  Determine the correlation of positive PCR results from peripheral blood with disease&#xD;
           stage.&#xD;
&#xD;
      OUTLINE: Lymph node biopsies or peripheral blood are obtained from patients. These specimens&#xD;
      are examined by nested reverse transcriptase-polymerase chain reaction (RT-PCR) and analyzed&#xD;
      for various tumor antigens.&#xD;
&#xD;
      Patients may choose to be told the results of this testing, but the results do not influence&#xD;
      or change the planned therapy. Brief counseling is required to discuss the results and their&#xD;
      potential implications.&#xD;
&#xD;
      Patients are followed for at least 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients for the lymph node portion and 80 patients (20 per&#xD;
      stage of disease) for the peripheral blood portion will be accrued for this study within 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if there is a suggestion that PCR-positive lymph nodes predict relapse of disease</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">106</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Clinically proven melanoma with indication to perform sentinel lymph node biopsy or&#xD;
             elective lymph node dissection OR&#xD;
&#xD;
          -  Histologically proven or diagnosis highly suspicious for melanoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count greater than 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 7 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT less than 15 sec&#xD;
&#xD;
          -  PTT less than 30 sec&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No psychiatric illness that precludes compliance&#xD;
&#xD;
          -  No other concurrent malignancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F. Gajewski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I melanoma</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

